Glioblastoma; Malignant tumor; B-Vitamins; Malignant glioma; Central nervous system disease; Nervous system diseases; Vertebrata; Mammalia; Rodentia; Dose activity relation; Nicotinamide; Toxicity; Inhalation; Combined treatment; Treatment efficiency; Radiotherapy; Fractionated dose; Mouse; Animal; Souris; Glioblastome; Tumeur maligne; Vitamine B; Gliome malin; Système nerveux central pathologie; Système nerveux pathologie; Carbogène; Relation dose réponse; Toxicité; Traitement associé; Efficacité traitement; Radiothérapie; Dose fractionnée
Abstract :
[en] This study addressed the potential radiosensitizing effect of nicotinamide and/or carbogen on human glioblastoma xenografts in nude mice. U-87MG and LN-Z308 tumors were irradiated with either 20 fractions over 12 days or 5 fractions over 5 days in air-breathing mice, mice injected with nicotinamide, mice breathing carbogen, or mice receiving nicotinamide plus carbogen. The responses to treatment were assessed using local control and moist desquamation. In U-87MG tumors, the enhancement ratios (ERs) at the radiation dose required to produce local tumor control in 50% of the treated mice (TCD50) with nicotinamide and/or carbogen ranged from 1.13 to 1.24 for irradiation in 20 fractions over 12 days. In LN-Z308 tumors, the ERs at the TCD50 with nicotinamide and/or carbogen ranged from 1.22 to 1.40 for irradiation in 5 fractions over 5 days and from 1.11 to 1.30 in 20 fractions over 12 days, respectively. Skin injury was slightly enhanced, with ERs ranged from 1.06 to 1.15 when radiation was combined with carbogen and/or nicotinamide. Thus carbogen and nicotinamide can slightly improve the radiation response of human glioblastoma xenografts.
Disciplines :
Oncology
Author, co-author :
SUN, Lin-Quan; University Hospital of Lausanne > Radiation Oncology
BUCHEGGER, Franz; University Hospital of Geneva > Nuclear Medicine
Fractionated irradiation combined with carbogen breathing and nicotinamide of two human glioblastomas grafted in nude mice
Alternative titles :
[en] L'irradiation fractionnée combinée avec la respiration et la nicotinamide carbogène de deux glioblastomes humains greffés chez des souris nude.
Publication date :
January 2001
Journal title :
Radiation Research
ISSN :
0033-7587
Publisher :
Kluge Carden Jennnings Pub Co, Charlottesville, United States - Virginia
Volume :
155
Issue :
1
Peer reviewed :
Peer Reviewed verified by ORBi
Commentary :
Cette étude a porté sur l'effet potentiel de radiosensibilisation nicotinamide et / ou carbogène sur les xénogreffes de glioblastome humain chez la souris nude. U-87MG and LN-Z308 tumors were irradiated with either 20 fractions over 12 days or 5 fractions over 5 days in air-breathing mice, mice injected with nicotinamide, mice breathing carbogen, or mice receiving nicotinamide plus carbogen. U-87MG et LN-Z308 tumeurs ont été irradiées avec soit de 20 fractions de plus de 12 jours ou 5 fractions pendant 5 jours à l'air ambiant des souris, des souris injectées avec la nicotinamide, la souris à respirer carbogène, ou des souris recevant nicotinamide plus carbogène. The responses to treatment were assessed using local control and moist desquamation. Les réponses au traitement ont été évalués en utilisant le contrôle local et de desquamation. In U-87MG tumors, the enhancement ratios (ERs) at the radiation dose required to produce local tumor control in 50% of the treated mice (TCD(50)) with nicotinamide and/or carbogen ranged from 1.13 to 1.24 for irradiation in 20 fractions over 12 days. Dans U-87MG tumeurs, les ratios de valorisation (RE) à la dose de rayonnement requise pour produire de contrôle tumoral local dans 50% des souris traitées (TCD (50)) avec la nicotinamide et / ou carbogène variait de 1,13 à 1,24 pour l'irradiation dans 20 fractions de plus de 12 jours. In LN-Z308 tumors, the ERs at the TCD(50) with nicotinamide and/or carbogen ranged from 1.22 to 1.40 for irradiation in 5 fractions over 5 days and from 1.11 to 1.30 in 20 fractions over 12 days, respectively. En LN-Z308 tumeurs, les RÉ au TCD (50) avec la nicotinamide et / ou carbogène variait de 1,22 à 1,40 pour l'irradiation en 5 fractions sur 5 jours et de 1,11 à 1,30 en 20 fractions pendant 12 jours, respectivement. Skin injury was slightly enhanced, with ERs ranged from 1.06 to 1.15 when radiation was combined with carbogen and/or nicotinamide. Des lésions cutanées a été légèrement améliorée, avec ERS variait de 1,06 à 1,15 lorsque le rayonnement a été combinée avec carbogène et / ou de la nicotinamide. Thus carbogen and nicotinamide can slightly improve the radiation response of human glioblastoma xenografts. Ainsi carbogène et nicotinamide peut légèrement améliorer la réponse au rayonnement de xénogreffes de glioblastome humain.
Black P.M. (1991) Brain tumors. N. Engl. J. Med. 324:1555-1564.
Fallai C., Olmi P. (1997) Hyperfractionated and accelerated radiation therapy in central nervous system tumors (malignant gliomas, pediatric tumors, and brain metastases). Radiother. Oncol. 43:235-246.
Rojas A. (1991) Radiosensitization with normobaric oxygen and carbogen. Radiother. Oncol. 20(SUPPL.):65-70.
Griffin R.J., Okajima K., Barrios B., Song C.W. (1996) Mild temperature hyperthermia combined with carbogen breathing increases tumor partial pressure of oxygen (pO2) and radiosensitivity. Cancer Res. 56:5590-5593.
Fenton B.M. (1997) Effects of carbogen plus fractionated irradiation on KHT tumor oxygenation. Radiother. Oncol. 44:183-190.
Powell M.E.B., Hill S.A., Saunders M.I., Hoskin P.J., Chaplin D.J. (1997) Human tumor blood flow is enhanced by nicotinamide and carbogen breathing. Cancer Res. 57:5261-5264.
Fenton B.M., Lord E.M., Paoni S.F. (2000) Enhancement of tumor perfusion and oxygenation by carbogen and nicotinamide during single- and multifraction irradiation. Radiat. Res. 153:75-83.
Horsman M.R. (1995) Nicotinamide and other benzamide analogs as agents for overcoming hypoxic cell radiation resistance in tumors. Acta Oncol. 34:571-587.
Horsman M.R., Chaplin D.J., Brown J.M. (1989) Tumor radiosensitization by nicotinamide: A result of improved perfusion and oxygenation. Radiat. Res. 118:139-150.
Chaplin D.J., Horsman M.R., Trotter M.J. (1990) Effect of nicotinamide on the microregional heterogeneity of oxygen delivery within a murine tumor. J. Natl. Cancer Inst. 82:872-876.
Zheng H., Olive P.L. (1996) Reduction of tumor hypoxia and inhibition of DNA repair by nicotinamide after irradiation of SCCVII routine tumors and normal tissues. Cancer Res. 56:2801-2808.
Kjellen E., Joiner M.C., Collier J.M., Johns H., Rojas A. (1991) A therapeutic benefit from combining normobaric carbogen or oxygen with nicotinamide in fractionated X-ray treatments. Radiother. Oncol. 22:81-91.
Rojas A., Hirst V.K., Calvert A.S., Johns H. (1996) Carbogen and nicotinamide as radiosensitizers in a routine mammary carcinoma using conventional and accelerated radiotherapy. Int. J. Radiat. Oncol. Biol. Phys. 34:357-365.
Rojas A.M., Johns H., Fiat P.R. (1993) Should carbogen and nicotinamide be given throughout the full course of fractionated radiotherapy regimens?. Int. J. Radiat. Oncol. Biol. Phys. 27:1101-1105.
Siemann D.W., Horsman M.R., Chaplin D.J. (1994) The radiation response of KHT sarcomas following nicotinamide treatment and carbogen breathing. Radiother. Oncol. 31:117-122.
Van der Maazen R.W.M., Thijssen H.O.M., Kaanders J.H.A.M., De Koster A., Keyer A., Prick M.J.J., Grotenhuis J.A., Wesseling P., Van der Kogel A.J. (1995) Conventional radiotherapy combined with carbogen breathing and nicotinamide for malignant gliomas. Radiother. Oncol. 35:118-122.
Fatigante L., Ducci E., Cartei F., Colosimo S., Marini C., Prediletto R., Danesi R., Laddaga M., Del Tacca M., Caciagli P. (1997) Carbogen and nicotinamide combined with unconventional radiotherapy in glioblastoma multiforme: A new modality treatment. Int. J. Radiat. Oncol. Biol. Phys. 37:449-504.
Pickles T., Graham P., Syndikus I., Rheaume D.E., Duncan G.G., Green A., Marlow C. (1996) Tolerance of nicotinamide and carbogen with radiation therapy for glioblastoma. Radiother. Oncol. 40:245-247.
Lambin P., Poortmans P., Menten J., Hamers H.P. (1997) Accelerated radiotherapy with carbogen and nicotinamide (ARCON) in high grade malignant gliomas. Radiother. Oncol. 43:324.
Miralbell R., Mornex E., Greiner R., Bolla M., Storme E., Hulshof M., Bernier J., Denekamp J., Rojas A.M., Pierart M., Van Glabbeke M., Mirimanoff R.O. (1999) Accelerated radiotherapy, carbogen, and nicotinamide in glioblastoma multiforme: Report of European organization for research and treatment of cancer trial 22933. J. Clin. Oncol. 17:3143-3149.
Rampling R., Cruickshank G., Lewis A.D., Fitzsimmons S.A., Workman P. (1994) Direct measurement of pO2 distribution and bioreductire enzymes in human malignant brain tumors. J. Radiat. Oncol. Biol. Phys. 29:427-431.
Kayama T., Yoshimoto T., Fujimoto S., Sakurai Y. (1991) Intratumoral oxygen pressure in malignant brain tumors. J. Neurosurg. 74:55-59.
Stuben G., Stuschke M., Knuhmann K., Horsman M.R., Sack H. (1998) The effects of combined nicotinamide and carbogen treatments in human turnout xenografts: Oxygenation and turnout control studies. Radiother. Oncol. 48:143-148.
Van Melt E.G., Kikuchi T., Tada M., Li H., Diserens A.-C., Wojcik B.E., Huang H.J., Friedman T., De Tribolet N., Cavenee W.K. (1994) Analysis of the p 53 gene and its expression in human glioblastoma cells. Cancer Res. 54:649-652.
Sheldon P.W., Hill S.A. (1977) Hypoxic cell radiosensitizers and local control by X-ray of a transplanted turnout in mice. Br. J. Cancer 35:795-808.
Horsman M.R., Hoyer M., Honess D.J., Dennis I.F., Overgaard J. (1993) Nicotinamide pharmacokinetics in humans and mice: A comparative assessment and the implications for radiotherapy. Radiother. Oncol. 27:131-139.
Horsman M.R., Siemann D.W., Chaplin D.J., Overgaard J. (1997) Nicotinamide as a radiosensitizer in tumors and normal tissues: The importance of drug dose and timing. Radiother. Oncol. 45:167-174.
Fowler J.F., Kragt K., Ellis R.E., Lindop P.J., Berry B.J. (1965) The effects of divided doses of 15 MeV electrons on the skin response of mice. Int. J. Radiat. Biol. 9:241-252.
Begg A.C., Hofland I., Moonen L., Bartelink H., Schraub S., Bontemps P., Le Fur R., Van den Bogaert W., Caspers R., Van Glabbeke M. (1990) The predictive value of cell kinetic measurements in a European trial of accelerated fractionation in advanced head and neck tumors: An interim report. Int. J. Radiat. Oncol. Biol. Phys. 19:1449-1453.
Begg A.C., McNally N.J., Shrieve D.C., Karcher H.A. (1985) A method to measure the duration of DNA synthesis and the potential doubling time from a single sample. Cytometry 6:620-626.
Rojas A., Vojnovic B., Johns H., Joiner M.C., Martindale C., Fowler J.F., Denekamp J. (1996) Radiosensitisation in normal tissues with oxygen, carbogen or nicotinamide: Therapeutic gain comparisons for fractionated x-ray schedules. Radiother. Oncol. 39:53-64.
Bernsen H.J.J.A., Rijken P.F.J.W., Oostendorp T., Van der Kogel A.J. (1995) Vascular and perfusion of human gliomas xenografted in the athymic nude mice. Br. J. Cancer 71:721-726.
Raabe A., Rett M., Krull A., Beck-Bornholdt H.P. (1997) Combination of fractionated irradiation with nicotinamide and carbogen in RIH-tumours of the rat and its pulmonary metastases. Radiother. Oncol. 45:183-189.
Hulshof M.C., Rehmann C.J., Booij J., Van Royen E.A., Bosch D.A., Gonzalez Gonzalez D. (1998) Lack of perfusion enhancement after administration of nicotinamide and carbogen in patients with glioblastoma: A 99mTc-HMPAO SPECT study. Radiother. Oncol. 48:135-142.
Bernier J., Denekamp J., Rojas A., Trovo M., Horiot J.C., Hamers H., Antognoni P., Dahl O., Richaud P., Pierart M. (1999) ARCON: Accelerated radiotherapy with carbogen and nicotinamide in non small cell lung cancer: A phase I/II study by the EORTC. Radiother. Oncol. 52:149-156.
Kaanders J.H.A.M., Pop L.A.M., Mattes H.A.M., Liefers J., Van den Hoogen F.J.A., Van Daal W.A.J., Van der Kogel A.J. (1998) Accelerated radiotherapy with carbogen and nicotinamide (ARCON) for laryngeal cancer. Radiother. Oncol. 48:115-122.
Hoskin P.J., Saunders M.I., Dische S. (1999) Hypoxic radiosensitizers in radical radiotherapy for patients with bladder carcinoma: Hyperbaric oxygen, misonidazole, and accelerated radiotherapy, carbogen, and nicotinamide. Cancer 86:1322-1328.
Horsman M.R. (1997) Tolerance to nicotinamide and carbogen with radiation therapy for glioblastoma. Radiother. Oncol. 43:109-110.
